PL2074123T3 - Nowe związki o działaniu przeciwlękowym - Google Patents

Nowe związki o działaniu przeciwlękowym

Info

Publication number
PL2074123T3
PL2074123T3 PL07815371T PL07815371T PL2074123T3 PL 2074123 T3 PL2074123 T3 PL 2074123T3 PL 07815371 T PL07815371 T PL 07815371T PL 07815371 T PL07815371 T PL 07815371T PL 2074123 T3 PL2074123 T3 PL 2074123T3
Authority
PL
Poland
Prior art keywords
anxiolytic compounds
novel anxiolytic
novel
compounds
anxiolytic
Prior art date
Application number
PL07815371T
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Brad Sleebs
Bernard Luke Flynn
Ian Phillip Street
Nurul Quazi
Chinh Thien Bui
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of PL2074123T3 publication Critical patent/PL2074123T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07815371T 2006-10-16 2007-10-16 Nowe związki o działaniu przeciwlękowym PL2074123T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198306P 2006-10-16 2006-10-16
EP07815371A EP2074123B1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds
PCT/AU2007/001566 WO2008046135A1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds

Publications (1)

Publication Number Publication Date
PL2074123T3 true PL2074123T3 (pl) 2013-04-30

Family

ID=39313499

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07815371T PL2074123T3 (pl) 2006-10-16 2007-10-16 Nowe związki o działaniu przeciwlękowym

Country Status (12)

Country Link
US (7) US8293737B2 (pl)
EP (2) EP2540722B1 (pl)
JP (4) JP5373613B2 (pl)
AU (1) AU2007312936B2 (pl)
CA (2) CA2666219C (pl)
DK (1) DK2074123T3 (pl)
ES (1) ES2399071T3 (pl)
NZ (1) NZ576036A (pl)
PL (1) PL2074123T3 (pl)
PT (1) PT2074123E (pl)
SI (1) SI2074123T1 (pl)
WO (1) WO2008046135A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954231B2 (en) * 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
US8293737B2 (en) 2006-10-16 2012-10-23 Bionomics Limited Anxiolytic compounds
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
AU2012222874B2 (en) * 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
WO2014036595A1 (en) * 2012-09-04 2014-03-13 Bionomics Limited Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
AU2013204159B2 (en) 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound
HK1220191A1 (zh) * 2013-03-15 2017-04-28 Bionomics Limited 抗焦虑化合物的盐、共晶体和多晶型物
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
AU2019361539B2 (en) 2018-10-18 2025-03-06 Bionomics Limited Cyclic compounds as receptor modulating therapeutics and methods and uses thereof
CN114585362B (zh) * 2019-09-23 2024-05-07 生态有限公司 治疗制剂及其用途
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023129958A2 (en) 2021-12-28 2023-07-06 ATAI Life Sciences AG Nitric oxide releasing prodrugs of mda and mdma

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) * 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en) * 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) * 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
JPS5023036B1 (pl) 1970-12-29 1975-08-05
JPS5023037B1 (pl) 1970-12-29 1975-08-05
JPS5023037A (pl) * 1973-07-03 1975-03-12
JPS5023036A (pl) * 1973-07-06 1975-03-12
JPS5132594A (en) * 1974-09-11 1976-03-19 Kanebo Ltd 1 88 nafuchirijinjudotai no seiho
JPS5331690A (en) * 1976-09-01 1978-03-25 Shionogi & Co Ltd Oxadithiacephalosporins
JPS54163596A (en) * 1978-06-09 1979-12-26 Daiichi Seiyaku Co Flonaphlizine derivative
JPS55111486A (en) * 1979-02-19 1980-08-28 Dai Ichi Seiyaku Co Ltd Preparation of pro 3,2,-b -1,8-naphthyridine derivative
JPS55151584A (en) * 1979-05-11 1980-11-26 Dai Ichi Seiyaku Co Ltd Preparation of 1,8-naphthyridine derivative
JPS56115787A (en) * 1980-02-19 1981-09-11 Dai Ichi Seiyaku Co Ltd Preparation of furo (3,2-b)(1,8)naphthyridine derivative
JPS56118083A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)(1,8)naphthyridine derivative
JPS56118081A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Preparation of 6-methoxy-1,8-naphthyridine
JPS5726688A (en) * 1980-07-24 1982-02-12 Dai Ichi Seiyaku Co Ltd Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative
JPS57109790A (en) * 1980-12-26 1982-07-08 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative
US4404201A (en) 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
JPS5993080A (ja) * 1982-11-18 1984-05-29 Sumitomo Chem Co Ltd １，５−ナフチリジンカルボン酸誘導体
EP0341990B1 (en) * 1988-05-10 1994-11-09 Imperial Chemical Industries Plc Cephalosporins, process for their preparation and pharmaceutical compositions
US5095015A (en) * 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
US5182386A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
IT1251202B (it) * 1991-09-13 1995-05-04 Mediolanum Farmaceutici Spa 6-amminochinoloni, sintesi ed impiego come antibatterici
US5212310A (en) * 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5306819A (en) * 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5804686A (en) * 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6013650A (en) * 1996-03-14 2000-01-11 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
AU2218997A (en) * 1996-03-22 1997-10-10 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
US6143760A (en) * 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
EP1007526A1 (en) * 1997-08-25 2000-06-14 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
WO1999043682A1 (en) * 1998-02-26 1999-09-02 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives, their preparation and their use as (ant-)agonists for gaba (a) brain receptors
DE19826050A1 (de) 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
US6177569B1 (en) * 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
JP2002544197A (ja) * 1999-05-06 2002-12-24 ニューロゲン コーポレイション 置換４−オキソ−キノリン−３−カルボキサミド：ｇａｂａ脳受容体リガンド
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
ES2195943T3 (es) * 1999-11-12 2003-12-16 Neurogen Corp Compuestos heteroaromaticos biciclicos y triciclicos.
US6723332B2 (en) * 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
US6828329B2 (en) * 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6423956B1 (en) * 2000-07-28 2002-07-23 Optical Biopsy Technologies Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning
ATE307127T1 (de) * 2000-08-16 2005-11-15 Neurogen Corp 2,4-substituierte pyridinderivate
CA2419966A1 (en) * 2000-09-06 2002-03-14 Neurogen Corporation Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
CA2439581A1 (en) 2001-03-01 2002-09-12 Pfizer Products Inc. Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
MXPA03008681A (es) * 2001-03-27 2004-04-02 Neurogen Corp (oxo-pirazol[1,5]pirimidin-2-il)alquil-carboxamidas.
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
MXPA04011156A (es) * 2002-05-14 2005-02-17 Univ California Acidos quinoloncarboxilicos sustituidos, sus derivados, sitio de accion y usos de los mismos.
IS7839A (is) 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
TW200427688A (en) * 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
JP2005162726A (ja) * 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
US20050031652A1 (en) 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
WO2004083207A1 (en) * 2003-03-12 2004-09-30 Abbott Laboratories Naphthyridine derivatives as antibacterial agents
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) * 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004972B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
CA2554522A1 (en) * 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2006048146A1 (en) 2004-11-01 2006-05-11 F. Hoffmann-La Roche Ag Quinoline as allosteric enhancers of the gaba-b receptors
EP1819342A4 (en) 2004-12-03 2008-12-17 Merck & Co Inc QUINOLINE tachykinin ANTAGONISTS
MX2007014929A (es) 2005-06-02 2008-02-15 Hoffmann La Roche 3-metansulfonilquinolinas como mejoradores de gaba-b.
PT1931660E (pt) 2005-09-29 2012-10-30 Sanofi Sa Derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenilo, processos para a sua preparação e sua utilização como fármacos
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US8293737B2 (en) 2006-10-16 2012-10-23 Bionomics Limited Anxiolytic compounds
AR076687A1 (es) 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
AU2012222874B2 (en) 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
AU2012222869B2 (en) 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines

Also Published As

Publication number Publication date
JP5373613B2 (ja) 2013-12-18
JP2010506829A (ja) 2010-03-04
US8906912B2 (en) 2014-12-09
CA2666219C (en) 2017-02-07
US9975892B2 (en) 2018-05-22
US20130012508A1 (en) 2013-01-10
ES2399071T3 (es) 2013-03-25
JP2013189453A (ja) 2013-09-26
US8614212B2 (en) 2013-12-24
CA2954376C (en) 2019-06-11
WO2008046135A1 (en) 2008-04-24
EP2540722A1 (en) 2013-01-02
US9573945B2 (en) 2017-02-21
SI2074123T1 (sl) 2013-03-29
US20140045839A1 (en) 2014-02-13
PT2074123E (pt) 2013-01-22
HK1132268A1 (en) 2010-02-19
DK2074123T3 (da) 2013-01-14
JP6138191B2 (ja) 2017-05-31
US20100105678A1 (en) 2010-04-29
AU2007312936A1 (en) 2008-04-24
EP2074123A1 (en) 2009-07-01
NZ576036A (en) 2010-10-29
EP2540722B1 (en) 2016-06-08
AU2007312936B2 (en) 2013-09-26
US20170183347A1 (en) 2017-06-29
US20130012509A1 (en) 2013-01-10
US10233181B2 (en) 2019-03-19
US20180105524A1 (en) 2018-04-19
JP5739476B2 (ja) 2015-06-24
JP2015155444A (ja) 2015-08-27
EP2074123A4 (en) 2011-09-07
US8293737B2 (en) 2012-10-23
US20150166534A1 (en) 2015-06-18
CA2666219A1 (en) 2008-04-24
US8551990B2 (en) 2013-10-08
JP2017105818A (ja) 2017-06-15
EP2074123B1 (en) 2012-12-05
JP6506322B2 (ja) 2019-04-24
CA2954376A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
PL2074123T3 (pl) Nowe związki o działaniu przeciwlękowym
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP1981596A4 (en) NEW CONNECTIONS
EP1981900A4 (en) NEW COMPOUNDS
GB0603550D0 (en) Novel compounds
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0609117D0 (en) Novel compounds
GB0607840D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0608452D0 (en) Novel compounds
GB0624901D0 (en) Novel compounds E
GB0608457D0 (en) Novel compounds
GB0608299D0 (en) Novel Compounds
GB0602237D0 (en) Novel compounds
GB0602238D0 (en) Novel compounds
GB0602800D0 (en) Novel Compounds
GB0601305D0 (en) Novel compounds
GB0603900D0 (en) Novel compounds
GB0601728D0 (en) Novel Compounds
GB0609071D0 (en) Novel compounds
GB0608978D0 (en) Novel compounds